Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
REGENXBIO $140 million stock and pre-funded warrants offering
The stock is listed on the Nasdaq Global Select Market
iRhythm Technologies $661.25 million convertible senior notes offering
The 1.5% convertible senior notes are due 2029
Roche Holdings $3.875 billion notes offering
We advised Roche on the Rule 144A / Regulation S offering comprising four tranches of notes
Tandem Diabetes Care $316.25 million convertible senior notes offering
The 1.5% convertible senior notes are due 2029
LivaNova $345 million convertible notes offering and capped call transactions
The 2.5% convertible senior notes are due 2029
AbbVie $15 billion senior notes offering
The investment-grade offering comprised seven tranches
Bristol Myers Squibb $13 billion notes offering
The investment-grade offering comprised nine tranches
Cardinal Health $1.15 billion notes offering
The investment-grade notes are due 2029 and 2034
Prime Medicine $161 million stock and pre-funded warrants offering
The common stock is listed on the Nasdaq Global Market
Cigna $4.5 billion senior notes offering
The senior notes are due 2029, 2031, 2034 and 2054